<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Fosamprenavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i1019.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i1019.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i1019.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i391.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1135.htm" title="Previous: Etravirine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1112.htm" title="Next: Telbivudine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i1019">Fosamprenavir</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Fosamprenavir</b>
          has the following interaction information:
        </p><div>Fosamprenavir is a prodrug of amprenavir</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i118.htm" name="_118">Amiodarone</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of amiodarone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i1217.htm" name="_1217">Apixaban</a></td><td>avoidance of  fosamprenavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm" name="_1011">Aripiprazole</a></td><td class="cBV"><b> fosamprenavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td>caution with  fosamprenavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  fosamprenavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  fosamprenavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td> fosamprenavir may enhance or reduce anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1076.htm" name="_1076">Darifenacin</a></td><td>avoidance of  fosamprenavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  fosamprenavir reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  fosamprenavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir increased by etravirine (consider reducing dose of fosamprenavir)</b></td><td></td></tr><tr><td><a href="41001i120.htm" name="_120">Flecainide</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i302.htm" name="_302">Itraconazole</a></td><td>plasma concentration of both drugs may increase when  fosamprenavir given with itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm" name="_298">Ketoconazole</a></td><td> fosamprenavir increases plasma concentration of ketoconazole (also plasma concentration of fosamprenavir possibly increased)</td><td></td></tr><tr><td><a href="41001i55.htm" name="_55">Lidocaine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of lidocaine—avoid concomitant use</b></td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td>plasma concentration of  fosamprenavir reduced by lopinavir , effect on lopinavir plasma concentration not predictable—avoid concomitant use</td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td> fosamprenavir reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  fosamprenavir possibly reduced by nevirapine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  fosamprenavir possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i125.htm" name="_125">Propafenone</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of propafenone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm" name="_341">Quinine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b> fosamprenavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm" name="_200">Rifabutin</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of rifabutin (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir significantly reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm" name="_1136">Rivaroxaban</a></td><td>avoidance of  fosamprenavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm" name="_974">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  fosamprenavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm" name="_858">Sildenafil</a></td><td> fosamprenavir possibly increases plasma concentration of sildenafil </td><td></td></tr><tr><td><a href="41001i605.htm" name="_605">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  fosamprenavir given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> fosamprenavir increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm" name="_945">Tadalafil</a></td><td> fosamprenavir possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  fosamprenavir advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm" name="_946">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  fosamprenavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  fosamprenavir reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i850.htm" name="_850">Tolterodine</a></td><td>avoidance of  fosamprenavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm" name="_967">Vardenafil</a></td><td> fosamprenavir possibly increases plasma concentration of vardenafil </td><td></td></tr></tbody></table><p>Fosamprenavir belongs to <b>Antivirals</b>
          but <b>Antivirals</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1135.htm">Previous: Etravirine</a> | <a class="top" href="41001i1019.htm#">Top</a> | <a accesskey="]" href="41001i1112.htm">Next: Telbivudine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>